【2024AASLD】First-in-class: Dual-Targeting siRNA for the Functional Cure of Chronic Hepatitis B, SiranBio’s SA1211 Achieved Superb Combo Treatment Results by a Single Molecule

On November 18, 2024, Dr. Zhiwei Yang, the founder of SiranBio, gave an oral presentation on the latest pre-clinical results of SA1211 in the 2024 AASLD meeting at San Diego, California. SA1211 is a dual-targeting siRNA which can activate acquired immune response in addition to directly eradicate hepatitis B virus, and thus prevent viral rebound after the end of treatment.

[2024EASL]: Siran Bio Presents Core Data on Functional Cure of Anti-PD-L1 siRNA Pipeline SA012

The 2024 Annual Meeting of the European Association for the Study of the Liver (EASL) was held in Milan, Italy, from June 5-8, 2024. Siran Bio's anti-PD-L1 siRNA pipeline, SA012, was selected for an oral poster presentation at the conference due to its impressive results. Dr. Yang Zhiwei, the founder, was invited to attend the conference and shared the details of the poster data.

Siran Bio Presents at CRT2024 Conference in the US - Sharing Research Findings on SA016, a New Antihypertensive siRNA Drug

The Cardiovascular Research Technology (CRT) Meeting 2024 was held in Washington, D.C., USA from March 9th to 12th. Siran Bio was honored to be invited to present the research findings of SA016, a new drug for treating high blood pressure, at the CRT conference. On March 10th, Dr. Yang Zhiwei, the founder of Siran Bio, shared the non-clinical efficacy and safety of SA016 in Washington, which garnered great attention and recognition from the industry.